Xolair and Angina pectoris aggravated - a phase IV clinical study of FDA data

Summary:

Angina pectoris aggravated is reported as a side effect among people who take Xolair (omalizumab), especially for people who are female, 60+ old, have been taking the drug for 6 - 12 months also take Symbicort, and have High blood pressure.

The phase IV clinical study analyzes which people have Angina pectoris aggravated when taking Xolair. It is created by eHealthMe based on reports of 77,224 people who have side effects when taking Xolair from the FDA, and is updated regularly.

What is Xolair?

Xolair has active ingredients of omalizumab. It is often used in asthma. eHealthMe is studying from 77,554 Xolair users. Check the latest studies of Xolair.

What is Angina pectoris aggravated?

Angina pectoris aggravated (chest pain due to ischemia of the heart muscle) is found to be associated with 1,385 drugs and 643 conditions by eHealthMe. Check the latest studies of Angina pectoris aggravated.

On Jul, 06, 2026

77,224 people reported to have side effects when taking Xolair.
Among them, 229 people (0.3%) have Angina pectoris aggravated.

Could Xolair cause Angina pectoris aggravated?

Among these 229 people:

How long have people been on Xolair when they have Angina pectoris aggravated? *

Click here to view more results

What is the gender of people who have Angina pectoris aggravated when taking Xolair? *

Click here to view

What is the age of people who have Angina pectoris aggravated when taking Xolair? *

Click here to view more results

* Approximation only. Some reports may have incomplete information.

Do you take Xolair and have Angina pectoris aggravated?

- Check whether Angina pectoris aggravated is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Xolair:

Xolair (77,554 reports)

Angina pectoris aggravated treatments and more:

Angina pectoris aggravated (393 reports)

How severe was Angina pectoris aggravated and when was it recovered:

Angina pectoris aggravated in Xolair

Expand to all the drugs that have ingredients of omalizumab:

Angina pectoris aggravated and drugs with ingredients of omalizumab

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Xolair:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Angina pectoris aggravated:

Angina pectoris aggravated (1,385 drugs)

Browse all the conditions that are associated with Angina pectoris aggravated:

Angina pectoris aggravated (643 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on omalizumab (the active ingredients of Xolair) and Xolair (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.